We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > brentuximab vedotin

News List

Antibody-Drug Conjugates - Lessons Learned Neeta Ratanghayra
May 20, 2022
Antibody-drug conjugates (ADCs) have made significant progress in tumor therapy and show a promising future.
Breaking News! The Second ADC Approved for Marketing in China PharmaSources/Xiaoyaowan
May 21, 2020
According to the NMPA website on May 13, the marketing application for Brentuximab Vedotin Injection filed by Takeda Pharmaceutical in China has been reviewed and approved, to become the second ADC approved for marketing in China.
NICE backing for Keytruda in classical Hodgkin lymphoma pharmatimes
July 27, 2018
The National Institute for Health and Care Excellence has recommended that MSD’s Keytruda be funded on the NHS via the Cancer Drugs Fund (CDF) for a subgroup of people with relapsed or refractory classical Hodgkin lymphoma.
US expands scope of Seattle Genetics’ Adcetris pharmatimes
July 23, 2018
US regulators have approved Seattle Genetics’ Adcetris in combination with chemotherapy for adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma.